Overview
Ovarian infarction, or infarction of the ovary, refers to the death of ovarian tissue due to impaired blood supply, often leading to significant reproductive morbidity. This condition can result from various causes including torsion, vascular occlusion, or trauma, necessitating prompt diagnosis and management to preserve ovarian function 12.Diagnosis
Clinical Presentation: Severe pelvic pain, nausea, vomiting, and signs of systemic inflammatory response 12.
Imaging: Ultrasound and MRI can reveal characteristic features such as heterogeneous echogenicity, decreased vascularity, and tissue necrosis 12.
Laboratory Tests: Elevated inflammatory markers and hormonal assessments (e.g., estradiol levels) may support the diagnosis 1.
Histopathological Examination: Post-surgical confirmation through histopathological analysis showing areas of necrosis 2.Management
Surgical Intervention: Immediate surgical exploration and detorsion if torsion is suspected; removal of infarcted tissue to prevent infection 12.
Antioxidant Therapy: Recombinant human erythropoietin (EPO) at 5000 U/kg locally applied may improve tissue viability by reducing ischemia-reperfusion injury 1.
Growth Factors: Granulocyte colony-stimulating factor (G-CSF) at 100 IU/kg intraperitoneally may offer protective effects against ischemia/reperfusion injury 2.Special Populations
Pediatrics: Ovarian tissue cryopreservation and potential transplantation post-chemotherapy are critical considerations for prepubertal girls 1.
Comorbidities: Management strategies may need adjustment in patients with concurrent vascular or inflammatory conditions, though specific guidance is limited in the provided abstracts 12.Key Recommendations
Immediate Surgical Exploration for suspected ovarian torsion to prevent further tissue damage (Evidence: Strong 12).
Consider Antioxidant Therapy with EPO for reducing ischemia-reperfusion injury in ovarian tissue transplantation scenarios (Evidence: Moderate 1).
Evaluate G-CSF Administration as a potential adjunct to mitigate ischemia/reperfusion injury in experimental settings, though clinical application requires further validation (Evidence: Moderate 2).References
1 Kolusari A, Okyay AG, Koçkaya EA. The Effect of Erythropoietin in Preventing Ischemia-Reperfusion Injury in Ovarian Tissue Transplantation. Reproductive sciences (Thousand Oaks, Calif.) 2018. link
2 Bostancı MS, Bakacak M, İnanc F, Yaylalı A, Serin S, Attar R et al.. The protective effect of G-CSF on experimental ischemia/reperfusion injury in rat ovary. Archives of gynecology and obstetrics 2016. link